ClinicalTrials.gg
CompletedNCT02279823Updated Mar 13, 2017

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

A Phase 2 interventional study of CB-03-01 solution and Minoxidil Solution 5% in Androgenetic Alopecia, sponsored by Intrepid Therapeutics, Inc.. Completed at 3 sites in United States. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-03-13.

Sponsored by Intrepid Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
43rd of 203
95 · median 40
Started
2014
with 5 others
Phase 2
47 of 216
6 open now
Registered
47th of 216
by date

Among the 216 studies in Alopecia with a site in United States, this one is the 43rd largest by enrollment of the 203 interventional ones that give a count, is one of 6 that started in 2014, is one of 47 in phase 2, and was the 47th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 50 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

Keywords

  • androgen
  • alopecia
  • CB-03-01
  • solution
  • topical
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has mild to moderate androgenetic alopecia (AGA) in temple and vertex region
  • Subject is willing to maintain the same hairstyle, hair length, and hair color throughout the study
  • Subject agrees to continue his other general hair care products and regimen for the entire study
  • Subjects who are sexually active with a female partner must be surgically sterile or agree to use an effective method of from the first administration of the test article until 30 days after the last administration

Exclusion criteria

Exclusion Criteria:

  • Subject has any dermatological disorders of the scalp in the target region with the possibility of interfering with the application of the test article or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars, or scalp atrophy
  • Subject has any condition in the opinion of the investigator that could interfere with the evaluation of the test articles or requires the use of interfering topical or systemic therapy (e.g., uncontrolled thyroid disease, certain genetic disorders that involve hair growth or patterns)
  • Subject has a current or recent history (within 3 months) of hair transplants, hair weaves or non-breathable wigs and hair bonding
  • Subject has a current or recent history (within 3 months) of active hair loss due to diffuse telogen effluvium, alopecia areata, scarring alopecia, trichotillomania or conditions/diseases other than AGA
  • Subject has a current or recent history (within 3 months) of severe dietary changes or presenting a history of eating disorder(s)
  • Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study
  • Subject is currently enrolled in an drug or device study
  • Subject has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment
  • Subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
  • Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
  • The subject has known or previous allergic reaction to any of the active or inactive components of the test articles or tattoo ink
  • Subject has used any of the following topical preparations or procedures on the scalp:

    • Topical treatments including , pimecrolimus, tacrolimus, minoxidil, hormone therapy, anti-androgens or other agents that are known to affect hair growth in the opinion of the investigator within 12 weeks of the initiation of treatment
    • Topical over-the-counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Aminexil, Maxilene, Nioxin, Foltene, etc. or hair health or hair growth products with saw palmetto, copper, etc.) in the opinion of the investigator within 4 weeks of the initiation of treatment.
    • Scalp procedures (surgical, laser, light or energy treatments, etc.) within 6 months of the initiation of treatment
  • Subject has used the following systemic medications or procedures:

    • Beta blockers, cimetidine, diazoxide, isotretinoin, vitamin A intake above 10000 IU per day or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of the initiation of treatment. Inhaled, intranasal or ocular corticosteroids are allowed if use is stable (stable use is defined as dose and frequency unchanged for at least 4 weeks prior to the initiation of treatment)
    • Retinoid, cyclosporine therapy within 6 months of the initiation of treatment
    • Finasteride (Propecia®, etc.), dutasteride or a similar product(s) within 12 months of the initiation of treatment
    • Chemotherapy, cytotoxic agents or radiation (of the scalp) within 12 months of the initiation of treatment
    • Other systemic therapy which may materially affect the subject's hair or hair growth in the opinion of the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    CB-03-01 solution

    Topical solution applied twice daily for 26 weeks

    Drug: CB-03-01 solution

  • Active comparator
    Minoxidil Solution 5%

    Topical solution applied twice daily for 26 weeks

    Drug: Minoxidil Solution 5%

  • Placebo comparator
    Placebo solution

    Topical solution applied twice daily for 26 weeks

    Drug: Placebo solution

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Target Area Hair Count (TAHC)

    Changes from Baseline in TAHC \[in number of non-vellus hairs\] using digital image analysis at Month 6.

    Time frame: Baseline and Month 6

  2. Subject Self Assessment (Hair Growth Assessment [HGA])

    The subject's evaluation of treatment benefit via the HGA questionnaires at Month 6. Scalp hair growth is compared from baseline using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3).

    Time frame: Month 6

Secondary outcomes

  1. Change in Target Area Hair Width (TAHW)

    Changes from Baseline in TAHW \[in μm/cm2\] using digital image analysis at Month 6.

    Time frame: Baseline and Month 6

  2. Change in Target Area Hair Density (TAHD)

    Changes from Baseline in TAHD \[in intensity units\] using digital image analysis at Month 6.

    Time frame: Baseline and Month 6

  3. Subject evaluation of treatment benefit via the Hair Growth Index (HGI) and Hair Growth Satisfaction Scale (HGSS) questionnaires

    The subject's evaluation of treatment benefit via the HGI and HGSS questionnaires at Month 6. HGI: Hair growth is compared from baseline by three questions on a health outcome questionnaire, which are scored using the following 7-point scale: much less (-3), moderately less (-2), slightly less (-1), the same amount (0), slightly more (1), moderately more (2), much more (3). HGSS: Hair appearance/growth is compared from baseline by five questions, which are scored using the following 7-point scale: very dissatisfied (-3), dissatisfied (-2), somewhat dissatisfied (-1), neutral/neither satisfied nor dissatisfied (0), somewhat satisfied (1), satisfied (2), very satisfied (3).

    Time frame: Month 6

  4. Investigator's Global Assessment (IGA)

    Compared to Baseline, the investigator will assess the subject's scalp hair growth using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3).

    Time frame: Baseline, Month 2, 4 and 6

07

Study locations

3 sites
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • DermResearch, Inc.
    Austin, Texas 78759, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Dec 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2014
First posted
Oct 31, 2014
Start
Oct 2014
Primary completionActual
Dec 2015
CompletionActual
May 2016
Results delay requested
Mar 9, 2017
Last update
Mar 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02279823
Lead sponsor
Intrepid Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 31, 2014
Start date
Oct 2014
Primary completion
Dec 2015
Completion
May 2016
Last update
Mar 13, 2017

Study contacts

Anthony Andrasfay
study director · Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion